Navigation Links
The Corporate Reputation of Pharma in 2012: The Patient Perspective on 29 of the World's Leading Pharma Companies

DUBLIN, November 28, 2013 /PRNewswire/ --

Research and Markets ( has announced the addition of the "The Corporate Reputation of Pharma in 2012: The Patient Perspective" report to their offering.


A global survey of the views of 600 international, national, and regional patient groups on the corporate reputation of the pharma industry and 29 leading pharma companies

Increasing numbers of pharmaceutical companies are seeking to redefine their relationships with patients, recasting their companies as more patient-centric. PatientView is therefore pleased to ANNOUNCE THE RELEASE of the latest version of its annual review.

- A global survey, conducted mid-November to mid-December 2012, exploring the views of 600 international, national, and regional patient groups from 56 countries (72% from Europe) and differing specialties

- Patient group feedback on the corporate reputation of the pharma industry during 2012.

- Patient group feedback provides rankings of 29 leading pharma companies for six key indicators that influence corporate reputation: patient-centredness; patient information; patient safety; useful products; transparency; and integrity.

- Results for 2012 are compared with those of 2011.

This independent study, funded by PatientView, represents 600 patient groups' latest impressions on the corporate reputation of 29 individual pharma companies and of the pharma industry as a whole. Results for 2012 are compared with 2011. For the purposes of this report, the phrase 'corporate reputation' is defined as the extent to which pharma companies are meeting the expectations of patients and patient groups.

Key findings industry-wide; reputation of pharma fell in 2012

The overall reputation of pharma declined in 2012. Only 34% of the 600 patient groups responding to the 2012 survey state that multinational pharma companies had an Excellent or Good reputation during 2012. The equivalent figure from the 500 patient groups responding to the 2011 survey was 42%. 40% of the 600 respondent patient groups state that the reputation of the pharma industry had declined during 2012. As many as 50% of the 600 respondent patient groups say that industry had a Poor record in 2012 for having fair pricing policies.48% of the 600 respondent patient groups say that industry had a Poor record in 2012 for being transparent.When the 2012 results are compared with those of 2011, the sharpest falls in pharma performance are for the following:

- Managing adverse news about producta 29% fall between 2011 and 2012.

- Having ethical marketing practicesa 23% fall between 2011 and 2012.

- Having a good relationship with the mediaa 19% fall, 2011-2012.

- Several reasons explain why pharma's reputation fell during 2012

Respondent patient groups report:

- a continuing failure to help patients in cash-strapped southern-European countries (such as Greece, Portugal, Romania, and Spain) gain access to medicines;

- a preoccupation by pharma with drugs that offer only short-term health benefits;

- not enough effort being made to discover chemical entities suitable for neglected catchments of patients;

- inappropriate marketing of drugs (including those for off-label indications);

- perceived lack of transparencyespecially in reporting the disappointing results of clinical trials;

- drugs prices that, in some cases, are still unaffordable to many patients or their payersculminating in a general impression that profit comes before making people well.

Companies Mentioned

- Abbott
- Allergan
- Amgen
- AstraZeneca
- Baxter International
- Bayer
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- Eli Lilly (Lilly)
- Gilead Sciences
- GlaxoSmithKline (GSK)
- Janssen
- Lundbeck
- Menarini
- Merck & Co (the US company)
- Merck Group (the German company)
- Novartis
- Novo Nordisk
- Pfizer
- Roche
- Sanofi
- Servier
- Shire
- Stada Arzneimittel
- Takeda
- Teva

For more information visit

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
2. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
3. Survey Shows eContent Critical to Corporate Strategies
4. Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With in Quarterly Series
5. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
6. Anatabloc® Retail Expansion with GNC Complete: Product Now Available at all GNC Corporate Stores and
7. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
8. Accuray Incorporated to Speak at Jefferies Global Healthcare Conference
9. InfuSystem Holdings Modifies Bylaws to Align with Corporate Governance Best Practices
10. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
11. Accuray Incorporated to Speak at Wells Fargo Healthcare Conference
Post Your Comments:
(Date:10/12/2015)... the United States . By early next year, the ... the United States . By early next year, the ... The University of Texas MD Anderson Cancer Center, Elekta and Philips ... MRI-guided linear accelerator in the United States . ... non-clinical capacity. Royal Philips (NYSE: PHG ; ...
(Date:10/12/2015)... , Oct. 12, 2015  The Pharmacy ... of Harbor Compounding Pharmacy in Costa ... in recognition of the pharmacy,s commitment to meeting ... --> ... --> --> ...
(Date:10/12/2015)... PARK, Calif. , Oct. 12, 2015 ... R&D and Chief Scientific Officer of Asterias ... biotechnology company in the emerging field of ... Dealmakers webcast, sponsored in part by Asterias ... Dr. Lebkowski will discuss the progress to ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... Altec ... their Title Sponsorship of Synergy 2015. The annual WennSoft KEY2ACT user conference will ... Ranch and will unite customers, partners, WennSoft team members and sponsors to facilitate ...
(Date:10/13/2015)... ... 13, 2015 , ... Georgia Partnership for TeleHealth ... Georgia, along with affiliate organizations, Alabama Partnership for Telehalth (ATP) and Florida Partnership ... Fall 2015. , Each of the three conferences share this year’s conference ...
(Date:10/13/2015)... ... October 13, 2015 , ... Local Gold’s Gym franchise owner, Bryce Berry, received ... 26. Berry, who owns and operates Gold's Gym Cheyenne in Cheyenne, Wyoming, ... in the United States. A brand leader in global fitness, Gold’s Gyms are located ...
(Date:10/13/2015)... ... October 13, 2015 , ... With Fall weather approaching ... tool for this month’s Facebook Hair Styler Contest. , Enter to win! , How ... Answering: What Is Your Favorite Hair Style? , 3. Follow us on Instagram ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... home furnishings and décor, today announced it closed on a $20.5 million funding ... will be used to support the Company’s continued rapid growth and expansion, broaden ...
Breaking Medicine News(10 mins):